256 related articles for article (PubMed ID: 24795896)
1. Targeting spleen tyrosine kinase-Bruton's tyrosine kinase axis for immunologically mediated glomerulonephritis.
Chen JS; Chang LC; Huang SJ; Cheng CW
Biomed Res Int; 2014; 2014():814869. PubMed ID: 24795896
[TBL] [Abstract][Full Text] [Related]
2. Development of a pharmacodynamic assay based on PLCγ2 phosphorylation for quantifying spleen tyrosine kinase (SYK)-Bruton's tyrosine kinase (BTK) signaling.
Hsu J; Zhang J; Kitson C; Tan SL; Narula S; DeMartino JA; Liao C
J Biomol Screen; 2013 Sep; 18(8):890-8. PubMed ID: 23704133
[TBL] [Abstract][Full Text] [Related]
3. Targeting the SYK-BTK axis for the treatment of immunological and hematological disorders: recent progress and therapeutic perspectives.
Tan SL; Liao C; Lucas MC; Stevenson C; DeMartino JA
Pharmacol Ther; 2013 May; 138(2):294-309. PubMed ID: 23396081
[TBL] [Abstract][Full Text] [Related]
4. Targeting the tyrosine kinase signalling pathways for treatment of immune-mediated glomerulonephritis: from bench to bedside and beyond.
Ma TK; McAdoo SP; Tam FW
Nephrol Dial Transplant; 2017 Jan; 32(suppl_1):i129-i138. PubMed ID: 28391340
[TBL] [Abstract][Full Text] [Related]
5. The future of B-cell lymphoma therapy: the B-cell receptor and its downstream pathways.
Kenkre VP; Kahl BS
Curr Hematol Malig Rep; 2012 Sep; 7(3):216-20. PubMed ID: 22688757
[TBL] [Abstract][Full Text] [Related]
6. Syk and Bruton's tyrosine kinase are required for B cell antigen receptor-mediated activation of the kinase Akt.
Craxton A; Jiang A; Kurosaki T; Clark EA
J Biol Chem; 1999 Oct; 274(43):30644-50. PubMed ID: 10521450
[TBL] [Abstract][Full Text] [Related]
7. Specific inhibition of spleen tyrosine kinase suppresses leukocyte immune function and inflammation in animal models of rheumatoid arthritis.
Coffey G; DeGuzman F; Inagaki M; Pak Y; Delaney SM; Ives D; Betz A; Jia ZJ; Pandey A; Baker D; Hollenbach SJ; Phillips DR; Sinha U
J Pharmacol Exp Ther; 2012 Feb; 340(2):350-9. PubMed ID: 22040680
[TBL] [Abstract][Full Text] [Related]
8. Comment on "Therapeutic targeting of Syk in autoimmune diabetes".
Kapoor S
J Immunol; 2011 Feb; 186(4):1885; author reply 1886-5. PubMed ID: 21289311
[No Abstract] [Full Text] [Related]
9. Phosphorylation of CD19 Y484 and Y515, and linked activation of phosphatidylinositol 3-kinase, are required for B cell antigen receptor-mediated activation of Bruton's tyrosine kinase.
Buhl AM; Cambier JC
J Immunol; 1999 Apr; 162(8):4438-46. PubMed ID: 10201980
[TBL] [Abstract][Full Text] [Related]
10. Selective inhibition of spleen tyrosine kinase (SYK) with a novel orally bioavailable small molecule inhibitor, RO9021, impinges on various innate and adaptive immune responses: implications for SYK inhibitors in autoimmune disease therapy.
Liao C; Hsu J; Kim Y; Hu DQ; Xu D; Zhang J; Pashine A; Menke J; Whittard T; Romero N; Truitt T; Slade M; Lukacs C; Hermann J; Zhou M; Lucas M; Narula S; DeMartino J; Tan SL
Arthritis Res Ther; 2013 Oct; 15(5):R146. PubMed ID: 24286216
[TBL] [Abstract][Full Text] [Related]
11. Transphosphorylation of Bruton's tyrosine kinase on tyrosine 551 is critical for B cell antigen receptor function.
Kurosaki T; Kurosaki M
J Biol Chem; 1997 Jun; 272(25):15595-8. PubMed ID: 9188445
[TBL] [Abstract][Full Text] [Related]
12. Identification of the SH2 domain binding protein of Bruton's tyrosine kinase as BLNK--functional significance of Btk-SH2 domain in B-cell antigen receptor-coupled calcium signaling.
Hashimoto S; Iwamatsu A; Ishiai M; Okawa K; Yamadori T; Matsushita M; Baba Y; Kishimoto T; Kurosaki T; Tsukada S
Blood; 1999 Oct; 94(7):2357-64. PubMed ID: 10498607
[TBL] [Abstract][Full Text] [Related]
13. The role of B-cell receptor inhibitors in the treatment of patients with chronic lymphocytic leukemia.
Wiestner A
Haematologica; 2015 Dec; 100(12):1495-507. PubMed ID: 26628631
[TBL] [Abstract][Full Text] [Related]
14. Regulation of protein kinase CbetaI by two protein-tyrosine kinases, Btk and Syk.
Kawakami Y; Kitaura J; Hartman SE; Lowell CA; Siraganian RP; Kawakami T
Proc Natl Acad Sci U S A; 2000 Jun; 97(13):7423-8. PubMed ID: 10852954
[TBL] [Abstract][Full Text] [Related]
15. Myeloid cell-mediated renal injury in rapidly progressive glomerulonephritis depends upon spleen tyrosine kinase.
Ryan J; Ma FY; Han Y; Ozols E; Kanellis J; Tesch GH; Nikolic-Paterson DJ
J Pathol; 2016 Jan; 238(1):10-20. PubMed ID: 26251216
[TBL] [Abstract][Full Text] [Related]
16. Noncatalytic Bruton's tyrosine kinase activates PLCγ
Wist M; Meier L; Gutman O; Haas J; Endres S; Zhou Y; Rösler R; Wiese S; Stilgenbauer S; Hobeika E; Henis YI; Gierschik P; Walliser C
J Biol Chem; 2020 Apr; 295(17):5717-5736. PubMed ID: 32184360
[TBL] [Abstract][Full Text] [Related]
17. A role for Bruton's tyrosine kinase in B cell antigen receptor-mediated activation of phospholipase C-gamma 2.
Takata M; Kurosaki T
J Exp Med; 1996 Jul; 184(1):31-40. PubMed ID: 8691147
[TBL] [Abstract][Full Text] [Related]
18. A targeted therapy for protein and lipid kinases in chronic lymphocytic leukemia.
Robak P; Robak T
Curr Med Chem; 2012; 19(31):5294-318. PubMed ID: 22830347
[TBL] [Abstract][Full Text] [Related]
19. Intracellular single-chain variable fragments directed to the Src homology 2 domains of Syk partially inhibit Fc epsilon RI signaling in the RBL-2H3 cell line.
Dauvillier S; Mérida P; Visintin M; Cattaneo A; Bonnerot C; Dariavach P
J Immunol; 2002 Sep; 169(5):2274-83. PubMed ID: 12193692
[TBL] [Abstract][Full Text] [Related]
20. Effects of novel Btk and Syk inhibitors on platelet functions alone and in combination in vitro and in vivo.
Series J; Ribes A; Garcia C; Souleyreau P; Bauters A; Morschhauser F; Jürgensmeier JM; Sié P; Ysebaert L; Payrastre B
J Thromb Haemost; 2020 Dec; 18(12):3336-3351. PubMed ID: 32926549
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
